Welcome to our dedicated page for Kamada SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents for a plasma-protein innovator can feel like clinical trial protocols. Kamada’s 10-K alone maps patent cliffs, manufacturing yields, and orphan-drug exclusivity across 200+ pages. If you’re hunting for “Kamada insider trading Form 4 transactions” before pivotal data releases, or need the fine print on a distribution partnership buried in an 8-K, the search can be time-consuming.
Stock Titan solves that problem. Our AI parses every newly posted filing, turning Kamada’s quarterly earnings report 10-Q filing into plain-English dashboards and flagging Form 4 insider transactions in real-time. Need “Kamada SEC filings explained simply” or a quick “Kamada earnings report filing analysis”? One click shows segment revenue trends, R&D cash burn, and upcoming regulatory milestones. You’ll also find:
- Instant alerts for “Kamada Form 4 insider transactions real-time”
- Concise highlights from the Kamada annual report 10-K simplified
- Key takeaways from each 8-K material events explained
- Links to the latest Kamada proxy statement executive compensation
Investors track Kamada’s plasma-fractionation capacity, Alpha-1 Antitrypsin sales, and clinical pipeline costs to gauge future cash flows. Our platform ties those datapoints directly to the source pages, making “understanding Kamada SEC documents with AI” part of your normal workflow. Whether you monitor “Kamada executive stock transactions Form 4” for sentiment or compare margins across quarters, Stock Titan delivers the context you need—without wading through biotech jargon.
Kamada Ltd. furnished a Form 6-K that includes a press release reporting strong third-quarter and nine‑month 2025 results, highlighting over 30% year‑over‑year profitability growth. The filing also provides a November 2025 company presentation and unaudited consolidated financial statements as of September 30, 2025. This 6‑K is incorporated by reference into Kamada’s Form S‑8 registration statements.
Kamada Ltd. furnished a Form 6-K and attached an exhibit announcing a clinical milestone for CYTOGAM. The filing states it is incorporated by reference into the company’s Form S-8 registration statements.
Exhibit 99.1 is titled “Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation.” This indicates the study is led by independent investigators and marks the start of patient enrollment focused on CMV prevention in kidney transplant recipients. The report was signed by Nir Livneh, Vice President General Counsel and Corporate Secretary.
Kamada Ltd. announced it will hold its Annual General Meeting of Shareholders on December 10, 2025 at 4:00 p.m. Israel time at the company’s offices, 2 Holzman Street, Weizmann Science Park, Rehovot, Israel.
The report states that the Notice and Proxy Statement and the proxy card are attached as Exhibits 99.1 and 99.2 and incorporated by reference. The Form 6-K is also incorporated by reference into Kamada’s Form S-8 registration statements (File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267, 333-265866).
Kamada Ltd (KMDA) reported stronger operating results in a Form 6-K filing that includes a company presentation and unaudited consolidated financial statements as of June 30, 2025. The company disclosed 11% year-over-year top-line growth for the first six months and a 35% increase in profitability over the same period. Management also raised full-year profitability guidance. The filing attaches the presentation and the Inline XBRL financial documents for more detail.
FAQ
What is the current stock price of Kamada (KMDA)?
What is the market cap of Kamada (KMDA)?
